GLOBUS MEDICAL INC acquired Nevro Corp. for approximately $250 million total equity value ($5.85 per share in cash), a transaction completed in April 2025, structured as all cash.
Nevro Corp. operates in Neuromodulation — chronic pain management, is based in Redwood City, California, USA. Nevro Corp. is a Redwood City, California global medical device company delivering comprehensive solutions for the treatment of chronic pain, known for its high-frequency (HFX) spinal cord stimulation technology.
Furthers Globus Medical's mission to become the preeminent musculoskeletal technology company by expanding into new markets for future growth and gaining access to differentiated technologies in neuromodulation, enabling technologies, and future implant solutions.
World-class, differentiated high-frequency neuromodulation technology opening a roughly $2 billion chronic-pain market opportunity for Globus. Globus expects its scale and operational discipline to optimize Nevro's financial performance and drive enhanced profitability. Integrated into Globus Medical; Nevro common stock ceased trading on the NYSE on April 3, 2025 Dan Scavilla, President and CEO, Globus Medical (April 3, 2025 completion release): "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much needed treatment option to patients suffering from chronic pain."
This transaction furthers our mission to become the preeminent musculoskeletal technology company in the world by enabling us to expand into new markets for future growth, while gaining access to world-class, differentiated technologies that can provide significant benefit in neuromodulation, enabling technologies, and future implant solutions.Dan Scavilla, President and CEO, Globus Medical
We are thrilled to join Globus Medical as this will allow us to reach more patients globally with clinically proven, innovative products that significantly reduce the burden of chronic pain.Kevin Thornal, CEO and President, Nevro Corp.
Advisory firms were not disclosed for this transaction.